Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Intervention Study to Evaluate the Impact of the Implementation of Standardized Transthyretin Amyloidosis (ATTR) Early Identification and Diagnosis in ATTR High Risk Population

NCT07338942 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07338942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07338942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Intervention Study to Evaluate the Impact of the Implementation of Standardized Transthyretin Amyloidosis (ATTR) Early Identification and Diagnosis in ATTR High Risk Population
Lead sponsor
AstraZeneca
Phase
Not applicable
Overall status
Active, not recruiting
Start date
April 21, 2026
Completion date
November 20, 2027
Enrollment
4,000 (estimated)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

attr-cm